NewsBenzingaATRenewの第3四半期調整後EPSは0.15ドルで、予想の0.10ドルを上回る。売上高は9億6,250万ドルで、予想の9億4,400万ドルを上回る。 ATRenewの第3四半期調整後EPSは0.15ドルで、予想の0.10ドルを上回る。売上高は9億6,250万ドルで、予想の9億4,400万ドルを上回る。 Benzinga 2026.11.19 08:06 (GMT+0) Open on Benzinga Other news Meta Halts Mark Zuckerberg’s New Share Issuance Plan Amid Investor Lawsuit Alleging CEO Pressured Board to Approve It Sunlands Technology Q3 EPS $0.41 Down From $1.31 YoY, Sales $49.500M Down From $73.472M YoY Anthropic IPO to Mint Thousands of Millionaires, With Seven Founders Becoming $10 Billion-Plus Billionaires Futu Holdings Q3 Sales $852.660M Beat $814.820M Estimate ATRenew Q3 Adj. EPS $0.15 Beats $0.10 Estimate, Sales $962.500M Beat $944.000M Estimate GSK’s Velzatinib Receives Japan Orphan Drug Designation For GIST, Supported By StrateGIST 1 Data; Adds To US FDA Fast Track, US, EU ODDs, Phase III Trials Under Way
Meta Halts Mark Zuckerberg’s New Share Issuance Plan Amid Investor Lawsuit Alleging CEO Pressured Board to Approve It
Anthropic IPO to Mint Thousands of Millionaires, With Seven Founders Becoming $10 Billion-Plus Billionaires
GSK’s Velzatinib Receives Japan Orphan Drug Designation For GIST, Supported By StrateGIST 1 Data; Adds To US FDA Fast Track, US, EU ODDs, Phase III Trials Under Way